Meningococcal group b vaccine - Biologic Drug Details

Summary for meningococcal group b vaccine

Tradenames:	2
High Confidence Patents:	0
Applicants:	2
BLAs:	2
Suppliers: see list	2
Recent Clinical Trials:	See clinical trials for meningococcal group b vaccine

Recent Clinical Trials for meningococcal group b vaccine

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Amgen	Phase 3
University of North Carolina, Chapel Hill	Phase 2
Cedars-Sinai Medical Center	Phase 2

See all meningococcal group b vaccine clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for meningococcal group b vaccine Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for meningococcal group b vaccine Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for meningococcal group b vaccine Derived from Patent Text Search

No patents found based on company disclosures

Meningococcal Group B Vaccine Market Dynamics and Financial Trajectory

Market Overview

The meningococcal vaccine market, including vaccines targeting serogroup B, is poised for significant growth over the next decade. Here are the key dynamics and financial projections for this segment.

Current Market Size and Growth Projections

As of 2024, the global meningococcal vaccine market is valued at approximately USD 3.95 billion and is expected to grow to USD 9.014 billion by 2034, reflecting a compound annual growth rate (CAGR) of 8.6%[1].

Drivers of Market Growth

Several factors are driving the growth of the meningococcal vaccine market, including:

Increasing Vaccination Initiatives

Government-backed immunization programs and mandates for vaccination in schools and universities are significantly boosting market demand. These initiatives are particularly prevalent in regions with high disease burdens[1].

Rising Incidence of Meningococcal Infections

The increasing incidence of meningococcal diseases, especially serogroup B, which has emerged as a leading cause of invasive meningococcal disease in several countries, is driving the demand for effective vaccines[1][4].

Technological Advancements

The development of conjugate and multivalent vaccines, which offer broader and longer-term protection, is a key growth factor. These vaccines are replacing traditional polysaccharide vaccines due to their superior immune response and durability[1][3].

Global Emphasis on Preventive Healthcare

There is a growing global emphasis on preventive healthcare measures, which includes increased investment in vaccination programs. This trend is supported by health organizations such as the World Health Organization (WHO) and Gavi, the Vaccine Alliance[1].

Regional Variations

Dominant Markets

North America and Europe are currently the largest markets for meningococcal vaccines, driven by robust healthcare infrastructures and high vaccination coverage. These regions benefit from strong government support for immunization programs and significant investments in vaccine research and development[1][3].

Emerging Markets

The Asia-Pacific region offers significant untapped potential, with growing government immunization initiatives and investments in public health programs. This region is expected to see substantial growth in the demand for meningococcal vaccines, particularly polysaccharide vaccines, due to their cost-effectiveness and high efficacy[1][3].

Vaccine Types and Their Impact

Conjugate Vaccines

Conjugate vaccines, such as Bexsero® and Trumenba®, are gaining prominence due to their ability to provide long-term immunity. These vaccines are particularly effective against serogroup B and are expected to continue driving market growth[1][4].

Polysaccharide Vaccines

Polysaccharide vaccines, despite being less effective in the long term, are still in high demand due to their cost-effectiveness and high efficacy in preventing meningococcal disease. They remain popular in both developed and emerging markets, especially in low and middle-income countries[3].

Cost-Effectiveness and Economic Considerations

High Vaccine Costs

One of the challenges facing the meningococcal vaccine market is the high cost of these vaccines. Studies have shown that routine MenB vaccination does not offer substantial value for money due to these high costs and the relatively low incidence of the disease[2].

Herd Immunity and Cost-Effectiveness

However, when herd effects are considered, the cost-effectiveness of MenB vaccines improves. Strategies that include adolescent vaccination have been found to offer the best value for money, while routine infant vaccination remains the most effective short-term strategy[2].

Economic Evaluations in Different Regions

In regions like Burkina Faso, mathematical models have shown that nationwide immunization campaigns using polyvalent meningococcal conjugate vaccines can be cost-effective, especially when integrated into the Expanded Program on Immunization (EPI)[5].

Challenges and Opportunities

Supply Chain Disruptions

Supply chain disruptions pose a significant challenge to the meningococcal vaccine market. Ensuring a stable supply chain is crucial for maintaining market growth and meeting demand[1].

Technological Innovation

Ongoing research and development to enhance vaccine efficacy and develop novel vaccines for emerging serogroups present future opportunities for market expansion. The introduction of pentavalent vaccines, which include protection against serotype B, is expected to further drive market growth[1][4].

Key Players and Market Concentration

The meningococcal vaccine market is characterized by a medium level of market concentration, with major players such as Pfizer, Sanofi, and GSK investing heavily in R&D and vaccine distribution. These companies are pivotal in driving innovation and expanding market reach[3].

Market Trends

Focus on Routine Immunization

There is a growing emphasis on routine immunization, particularly among high-risk groups such as adolescents and young adults. Public health organizations play a crucial role in promoting these vaccination programs, leading to increased sales and a stronger market outlook[3].

Innovation and Product Expansion

The development of new vaccines that offer broader protection against multiple serogroups is expected to sustain market growth. Major vaccine manufacturers are focusing on innovation to introduce these advanced vaccines, which will continue to drive the market forward[3].

Key Takeaways

• The meningococcal vaccine market is expected to grow significantly, driven by increasing vaccination initiatives, rising disease incidence, and technological advancements.
• Conjugate vaccines are replacing polysaccharide vaccines due to their long-term immunity benefits.
• North America and Europe are dominant markets, while the Asia-Pacific region offers significant growth potential.
• High vaccine costs and supply chain disruptions are key challenges, but ongoing R&D and government support are mitigating these issues.
• The market is expected to reach USD 9.014 billion by 2034, with a CAGR of 8.6%.

FAQs

What is the current market size of the meningococcal vaccine market?

The current market size of the meningococcal vaccine market is approximately USD 3.95 billion as of 2024[1].

What is the projected growth rate of the meningococcal vaccine market?

The meningococcal vaccine market is projected to grow at a compound annual growth rate (CAGR) of 8.6% from 2024 to 2034[1].

Which regions are the largest markets for meningococcal vaccines?

North America and Europe are currently the largest markets for meningococcal vaccines, driven by robust healthcare infrastructures and high vaccination coverage[1][3].

What are the main drivers of the meningococcal vaccine market growth?

The main drivers include increasing vaccination initiatives, rising incidence of meningococcal infections, technological advancements, and a global emphasis on preventive healthcare measures[1].

Are conjugate vaccines more effective than polysaccharide vaccines?

Yes, conjugate vaccines are more effective in providing long-term immunity compared to polysaccharide vaccines, which is why they are rapidly replacing the latter[1][3].

What are the challenges facing the meningococcal vaccine market?

High vaccine costs and supply chain disruptions are significant challenges, although ongoing R&D and government support are helping to mitigate these issues[1][2].

Sources

1. GlobeNewswire: Meningococcal Vaccine Market is Set to Grow from USD 3,950.2 Million in 2024 to USD 9,014 Million by 2034, Registering a Robust CAGR of 8.6% - FMI[1].
2. PubMed: Economic evaluation of meningococcal serogroup B (MenB) vaccines[2].
3. Mordor Intelligence: Meningococcal Vaccines Market - Trends, Size & Overview[3].
4. Grand View Research: Meningococcal Vaccines Market Size & Share Report, 2030[4].
5. PLOS Medicine: The cost-effectiveness of alternative vaccination strategies ...[5].